Clinical study protocol template
A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma Document type: Clinical Trial Protocol EUDRACT number: 2017-001273-16 Version number: 00 (OriginalProtocol) Clinical trial phase:III
Download Clinical study protocol template
Information
Domain:
Source:
Link to this page:
Documents from same domain
New antibiotic treatment options for uncomplicated ...
clinicaltrials.govtreatment options for gonorrhoea and only a few new drugs in the development pipeline, it is important to test existing antibiotics for their efficacy in gonorrhoea treatment. Objective : This project aims to identify new treatment modalities for uncomplicated gonorrhoea using
A PROSPECTIVE MULTI CENTER RANDOMIZED CONTROLLED …
clinicaltrials.govconjunction with Ceramic on Ceramic and Taperloc Complete Microplastyarticulation stem in primary total hip arthroplasty compared to patients who received the Exceed ABT Acetabular system with the same combination.
Title: A Phase 1, Randomized, Double-Blind, Placebo ...
clinicaltrials.govA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects Phase 1 TAK-653 Escalating Single and Multiple Dose Study in Healthy Subjects Sponsor: Takeda Development Centre Europe Ltd. 61 Aldwych London, WC2B 4AE United Kingdom
Statistical Analysis Plan (SAP) - ClinicalTrials.gov
clinicaltrials.govstatistical analysis. The subsections below will describe analyses in addition to the descriptive statistics. 6.1 Primary outcome The primary analysis will compare intervention groups (water supplementation vs control treatment) on their mean change in fasting plasma glucose between baseline and 12 months using a linear mixed model.
A Phase II, Randomized, Double -blind, Placebo -controlled ...
clinicaltrials.gov• International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated Guideline. • All applicable laws and regulations, including, without limitation, data privacy laws and regulations. • Regulatory requirements for reporting serious …
Clinical Study Report (CSR) Template (Drug and Device)
clinicaltrials.govATC Anatomical Therapeutic Chemical CFB change from baseline DHA dapsone hydroxylamine eCRF electronic case report form IGA Investigator’s Global Assessment MedDRA Medication Dictionary for Regulatory Activities mITT modified intent-to-treat NAD N-acetyl dapsone PK pharmacokinetic ...
Research Proposal - ClinicalTrials.gov
clinicaltrials.govas fecal microbiota transplantation (FMT). 4. Procedures Tissue samples will be obtained from consenting patients at (SDMCUT), or other relevant facilities (see section 6.i below), in accordance with protocols approved by the University of Texas Institutional Review Board (UTIRB). Patients who meet eligibility criteria will have their
Novartis CSR template
clinicaltrials.gov9.1 Study design Figure 9-1 Study design BID: twice a day, QD: once a day. This was a multicenter, randomized, double-masked, two-arm, placebo-controlled, parallel-group study in patients with normal tension glaucoma who were insufficiently controlled on travoprost 0.004% (Travatan) monotherapy. Approximately 200 patients were planned to be
DETAILED STATISTICAL ANALYSIS PLAN (SAP)
clinicaltrials.govStatistical principles : 4.1. Multiplicity : The diagnostic and prognostic basic stud y and each sub -study consist of one primary outcome and one or more secondary, exploratory outcomes. We will encounter multiplicity issues due to the multiple
Title: TWILIGHT Study - Ticagrelor With Aspirin or Alone ...
clinicaltrials.govPrior stroke Dialysis-dependent renal failure Active bleeding or extreme-risk for major bleeding (e.g. acute ... Life expectancy < 1 year ... 7.3.4 Adverse Events based on signs and symptoms ...
Related documents
Common Terminology Criteria for Adverse Events (CTCAE)
ctep.cancer.govCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 . Published: November 27, 2017 . U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES . National Institutes of Health
Vaccine Adverse Event Reporting System (VAERS) Standard ...
www.cdc.govNov 07, 2020 · 2.4 Review of VAERS forms and medical records for reports of interest 17 2.5 Signal assessment 19 3.0 Coordination and Collaboration 19
COVID-19 Vaccine AstraZeneca - Embolic and thrombotic ...
www.ema.europa.euA cumulative review of reports of Embolic and thrombotic events (SMQ Broad). The review should include at a minimum a discussion of fatal and serious events, if any batch clustering is observed with focus on ABV5300 batch, other risk factors – if they can be identified, an observed versus expected analysis, and risk-benefit considerations. 3.
ACIP-Thrombosis with thrombocytopenia syndrome (TTS ...
www.cdc.govApr 23, 2021 · MedDRA PTs for large vessel thrombosis and/or embolism (any report) ... Additional potential TTS cases under review, including potential male cases. 21. Confirmed reports of TTS following Janssen COVID -19 ... 12 cases were cerebral venous sinus thrombosis (CVST) Pregnant or post-partum* (n=0) COVID9 disease (n=2); both by history, no ...
2020 Annual Report on EudraVigilance for the European ...
www.ema.europa.eu2020 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission EMA/620104/2020 Page 5/37 by European patients and consumers through the NCAs and MAHs (143,958) has had a decrease of